Stockscreener 앱 받기
13.86
7.54%
-1.13
시간 외 거래:
13.85
-0.010
-0.07%
전일 마감가:
$14.99
열려 있는:
$14.69
하루 거래량:
19,706
Relative Volume:
0.82
시가총액:
$29.70M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-44.71
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
-8.21%
1개월 성능:
-6.29%
6개월 성능:
+23.75%
1년 성능:
+108.67%
1일 변동 폭
$13.67
$14.69
1주일 범위
$13.67
$15.99
52주 변동 폭
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
CVKD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
13.86 | 29.70M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Down 0.1% – Here’s What Happened - Defense World
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - BioSpace
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - BioSpace
(CVKD) Technical Pivots with Risk Controls - news.stocktradersdaily.com
What is Zacks Small Cap’s Estimate for CVKD FY2025 Earnings? - Defense World
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - MSN
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin - Research Tree
Cadrenal Therapeutics (NASDAQ:CVKD) Earns Buy Rating from HC Wainwright - Defense World
(CVKD) Proactive Strategies - news.stocktradersdaily.com
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Cadrenal Therapeutics (CVKD) Receives Buy Rating from HC Wainwright & Co. | CVKD Stock News - GuruFocus
Cadrenal Therapeutics advances in tecarfarin production By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics advances in tecarfarin production - Investing.com
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
Cadrenal Therapeutics, Inc. Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - marketscreener.com
Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 forNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 - openPR.com
Shares Of This EV Stock Soar On Year-Over-Year Guidance - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) | FinancialContent - FinancialContent
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD | FinancialContent - FinancialContent
Cisco Expands Partnership with Saudi Arabia to Power the AI Future - The Globe and Mail
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
CADRENAL THERAPEUTICS Earnings Preview: Recent $CVKD Insider Trading, Hedge Fund Activity, and More - Nasdaq
10,554 Shares in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Purchased by Geode Capital Management LLC - Defense World
Cadrenal Therapeutics (CVKD) to Release Quarterly Earnings on Thursday - Defense World
Sprott Asset Management buying more Sprott Phys. Copper Trust (COP) - The Globe and Mail
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World
Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace
Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan
Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):